Identifying high-risk candidates for prolonging progression-free survival in primary gastric carcinoma subject to “double invasion”: an analytical approach utilizing lasso-cox regression
To identify high-risk gastric carcinoma patients with concurrent vascular and neural invasion ("double invasion") who are at heightened risk of progression-free survival (PFS) decline, enabling personalized clinical management. In this multi-center retrospective study, 559 patients with do...
Saved in:
Published in | BMC cancer Vol. 25; no. 1; pp. 381 - 16 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
England
BioMed Central Ltd
28.02.2025
BioMed Central BMC |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | To identify high-risk gastric carcinoma patients with concurrent vascular and neural invasion ("double invasion") who are at heightened risk of progression-free survival (PFS) decline, enabling personalized clinical management.
In this multi-center retrospective study, 559 patients with double invasion who underwent curative gastrectomy between May 2002 and December 2020 were analyzed. Prognostic factors for PFS were identified using Lasso-Cox regression. Model validation included internal bootstrapping, calibration plots, and comparison against the American Joint Committee on Cancer(AJCC) 8th edition TNM staging system via Harrell's C-index, decision curve analysis (DCA), and time-dependent receiver operating characteristic (ROC) curves.
The nomogram integrated gender, positive lymph node count, surgical gastrectomy method, PTEN/FHIT expression levels, and maximum tumor diameter. It demonstrated superior predictive accuracy to AJCC staging, with a C-index of 0.651 (95% CI: 0.612-0.691) versus 0.543 (95% CI: 0.517-0.569). Calibration plots showed strong agreement between predicted and observed outcomes. The area under the curve(AUC) for 3- and 5-year PFS predictions were 0.719 (95% CI: 0.655-0.771) and 0.767 (95% CI: 0.670-0.841), respectively. DCA confirmed clinical utility across decision thresholds, and risk stratification effectively differentiated low- and high-risk groups. In the training cohort, the model significantly outperformed AJCC staging (NRI: 0.218, p < 0.01; IDI: 0.085, p < 0.01). However, this superiority was not statistically significant in the validation cohort (NRI: 0.141, p = 0.08; IDI: 0.031, p = 0.239).
We developed a Lasso-Cox regression-based nomogram to stratify PFS risk in gastric carcinoma patients with double invasion. While the model outperformed AJCC staging in training, validation cohort results highlight the need for further refinement. This tool holds potential for guiding tailored therapeutic strategies, though broader validation is warranted to confirm clinical applicability. |
---|---|
AbstractList | ObjectiveTo identify high-risk gastric carcinoma patients with concurrent vascular and neural invasion (“double invasion”) who are at heightened risk of progression-free survival (PFS) decline, enabling personalized clinical management.MethodsIn this multi-center retrospective study, 559 patients with double invasion who underwent curative gastrectomy between May 2002 and December 2020 were analyzed. Prognostic factors for PFS were identified using Lasso-Cox regression. Model validation included internal bootstrapping, calibration plots, and comparison against the American Joint Committee on Cancer(AJCC) 8th edition TNM staging system via Harrell’s C-index, decision curve analysis (DCA), and time-dependent receiver operating characteristic (ROC) curves.ResultsThe nomogram integrated gender, positive lymph node count, surgical gastrectomy method, PTEN/FHIT expression levels, and maximum tumor diameter. It demonstrated superior predictive accuracy to AJCC staging, with a C-index of 0.651 (95% CI: 0.612–0.691) versus 0.543 (95% CI: 0.517–0.569). Calibration plots showed strong agreement between predicted and observed outcomes. The area under the curve(AUC) for 3- and 5-year PFS predictions were 0.719 (95% CI: 0.655–0.771) and 0.767 (95% CI: 0.670–0.841), respectively. DCA confirmed clinical utility across decision thresholds, and risk stratification effectively differentiated low- and high-risk groups. In the training cohort, the model significantly outperformed AJCC staging (NRI: 0.218, p < 0.01; IDI: 0.085, p < 0.01). However, this superiority was not statistically significant in the validation cohort (NRI: 0.141, p = 0.08; IDI: 0.031, p = 0.239).ConclusionWe developed a Lasso-Cox regression-based nomogram to stratify PFS risk in gastric carcinoma patients with double invasion. While the model outperformed AJCC staging in training, validation cohort results highlight the need for further refinement. This tool holds potential for guiding tailored therapeutic strategies, though broader validation is warranted to confirm clinical applicability. To identify high-risk gastric carcinoma patients with concurrent vascular and neural invasion ("double invasion") who are at heightened risk of progression-free survival (PFS) decline, enabling personalized clinical management. In this multi-center retrospective study, 559 patients with double invasion who underwent curative gastrectomy between May 2002 and December 2020 were analyzed. Prognostic factors for PFS were identified using Lasso-Cox regression. Model validation included internal bootstrapping, calibration plots, and comparison against the American Joint Committee on Cancer(AJCC) 8th edition TNM staging system via Harrell's C-index, decision curve analysis (DCA), and time-dependent receiver operating characteristic (ROC) curves. The nomogram integrated gender, positive lymph node count, surgical gastrectomy method, PTEN/FHIT expression levels, and maximum tumor diameter. It demonstrated superior predictive accuracy to AJCC staging, with a C-index of 0.651 (95% CI: 0.612-0.691) versus 0.543 (95% CI: 0.517-0.569). Calibration plots showed strong agreement between predicted and observed outcomes. The area under the curve(AUC) for 3- and 5-year PFS predictions were 0.719 (95% CI: 0.655-0.771) and 0.767 (95% CI: 0.670-0.841), respectively. DCA confirmed clinical utility across decision thresholds, and risk stratification effectively differentiated low- and high-risk groups. In the training cohort, the model significantly outperformed AJCC staging (NRI: 0.218, p < 0.01; IDI: 0.085, p < 0.01). However, this superiority was not statistically significant in the validation cohort (NRI: 0.141, p = 0.08; IDI: 0.031, p = 0.239). We developed a Lasso-Cox regression-based nomogram to stratify PFS risk in gastric carcinoma patients with double invasion. While the model outperformed AJCC staging in training, validation cohort results highlight the need for further refinement. This tool holds potential for guiding tailored therapeutic strategies, though broader validation is warranted to confirm clinical applicability. Objective To identify high-risk gastric carcinoma patients with concurrent vascular and neural invasion ("double invasion") who are at heightened risk of progression-free survival (PFS) decline, enabling personalized clinical management. Methods In this multi-center retrospective study, 559 patients with double invasion who underwent curative gastrectomy between May 2002 and December 2020 were analyzed. Prognostic factors for PFS were identified using Lasso-Cox regression. Model validation included internal bootstrapping, calibration plots, and comparison against the American Joint Committee on Cancer(AJCC) 8th edition TNM staging system via Harrell's C-index, decision curve analysis (DCA), and time-dependent receiver operating characteristic (ROC) curves. Results The nomogram integrated gender, positive lymph node count, surgical gastrectomy method, PTEN/FHIT expression levels, and maximum tumor diameter. It demonstrated superior predictive accuracy to AJCC staging, with a C-index of 0.651 (95% CI: 0.612-0.691) versus 0.543 (95% CI: 0.517-0.569). Calibration plots showed strong agreement between predicted and observed outcomes. The area under the curve(AUC) for 3- and 5-year PFS predictions were 0.719 (95% CI: 0.655-0.771) and 0.767 (95% CI: 0.670-0.841), respectively. DCA confirmed clinical utility across decision thresholds, and risk stratification effectively differentiated low- and high-risk groups. In the training cohort, the model significantly outperformed AJCC staging (NRI: 0.218, p < 0.01; IDI: 0.085, p < 0.01). However, this superiority was not statistically significant in the validation cohort (NRI: 0.141, p = 0.08; IDI: 0.031, p = 0.239). Conclusion We developed a Lasso-Cox regression-based nomogram to stratify PFS risk in gastric carcinoma patients with double invasion. While the model outperformed AJCC staging in training, validation cohort results highlight the need for further refinement. This tool holds potential for guiding tailored therapeutic strategies, though broader validation is warranted to confirm clinical applicability. Keywords: Gastric cancer, Progression-free survival, Nomogram, Risk stratification, Vascular invasion and neural invasion To identify high-risk gastric carcinoma patients with concurrent vascular and neural invasion ("double invasion") who are at heightened risk of progression-free survival (PFS) decline, enabling personalized clinical management.OBJECTIVETo identify high-risk gastric carcinoma patients with concurrent vascular and neural invasion ("double invasion") who are at heightened risk of progression-free survival (PFS) decline, enabling personalized clinical management.In this multi-center retrospective study, 559 patients with double invasion who underwent curative gastrectomy between May 2002 and December 2020 were analyzed. Prognostic factors for PFS were identified using Lasso-Cox regression. Model validation included internal bootstrapping, calibration plots, and comparison against the American Joint Committee on Cancer(AJCC) 8th edition TNM staging system via Harrell's C-index, decision curve analysis (DCA), and time-dependent receiver operating characteristic (ROC) curves.METHODSIn this multi-center retrospective study, 559 patients with double invasion who underwent curative gastrectomy between May 2002 and December 2020 were analyzed. Prognostic factors for PFS were identified using Lasso-Cox regression. Model validation included internal bootstrapping, calibration plots, and comparison against the American Joint Committee on Cancer(AJCC) 8th edition TNM staging system via Harrell's C-index, decision curve analysis (DCA), and time-dependent receiver operating characteristic (ROC) curves.The nomogram integrated gender, positive lymph node count, surgical gastrectomy method, PTEN/FHIT expression levels, and maximum tumor diameter. It demonstrated superior predictive accuracy to AJCC staging, with a C-index of 0.651 (95% CI: 0.612-0.691) versus 0.543 (95% CI: 0.517-0.569). Calibration plots showed strong agreement between predicted and observed outcomes. The area under the curve(AUC) for 3- and 5-year PFS predictions were 0.719 (95% CI: 0.655-0.771) and 0.767 (95% CI: 0.670-0.841), respectively. DCA confirmed clinical utility across decision thresholds, and risk stratification effectively differentiated low- and high-risk groups. In the training cohort, the model significantly outperformed AJCC staging (NRI: 0.218, p < 0.01; IDI: 0.085, p < 0.01). However, this superiority was not statistically significant in the validation cohort (NRI: 0.141, p = 0.08; IDI: 0.031, p = 0.239).RESULTSThe nomogram integrated gender, positive lymph node count, surgical gastrectomy method, PTEN/FHIT expression levels, and maximum tumor diameter. It demonstrated superior predictive accuracy to AJCC staging, with a C-index of 0.651 (95% CI: 0.612-0.691) versus 0.543 (95% CI: 0.517-0.569). Calibration plots showed strong agreement between predicted and observed outcomes. The area under the curve(AUC) for 3- and 5-year PFS predictions were 0.719 (95% CI: 0.655-0.771) and 0.767 (95% CI: 0.670-0.841), respectively. DCA confirmed clinical utility across decision thresholds, and risk stratification effectively differentiated low- and high-risk groups. In the training cohort, the model significantly outperformed AJCC staging (NRI: 0.218, p < 0.01; IDI: 0.085, p < 0.01). However, this superiority was not statistically significant in the validation cohort (NRI: 0.141, p = 0.08; IDI: 0.031, p = 0.239).We developed a Lasso-Cox regression-based nomogram to stratify PFS risk in gastric carcinoma patients with double invasion. While the model outperformed AJCC staging in training, validation cohort results highlight the need for further refinement. This tool holds potential for guiding tailored therapeutic strategies, though broader validation is warranted to confirm clinical applicability.CONCLUSIONWe developed a Lasso-Cox regression-based nomogram to stratify PFS risk in gastric carcinoma patients with double invasion. While the model outperformed AJCC staging in training, validation cohort results highlight the need for further refinement. This tool holds potential for guiding tailored therapeutic strategies, though broader validation is warranted to confirm clinical applicability. Abstract Objective To identify high-risk gastric carcinoma patients with concurrent vascular and neural invasion (“double invasion”) who are at heightened risk of progression-free survival (PFS) decline, enabling personalized clinical management. Methods In this multi-center retrospective study, 559 patients with double invasion who underwent curative gastrectomy between May 2002 and December 2020 were analyzed. Prognostic factors for PFS were identified using Lasso-Cox regression. Model validation included internal bootstrapping, calibration plots, and comparison against the American Joint Committee on Cancer(AJCC) 8th edition TNM staging system via Harrell’s C-index, decision curve analysis (DCA), and time-dependent receiver operating characteristic (ROC) curves. Results The nomogram integrated gender, positive lymph node count, surgical gastrectomy method, PTEN/FHIT expression levels, and maximum tumor diameter. It demonstrated superior predictive accuracy to AJCC staging, with a C-index of 0.651 (95% CI: 0.612–0.691) versus 0.543 (95% CI: 0.517–0.569). Calibration plots showed strong agreement between predicted and observed outcomes. The area under the curve(AUC) for 3- and 5-year PFS predictions were 0.719 (95% CI: 0.655–0.771) and 0.767 (95% CI: 0.670–0.841), respectively. DCA confirmed clinical utility across decision thresholds, and risk stratification effectively differentiated low- and high-risk groups. In the training cohort, the model significantly outperformed AJCC staging (NRI: 0.218, p < 0.01; IDI: 0.085, p < 0.01). However, this superiority was not statistically significant in the validation cohort (NRI: 0.141, p = 0.08; IDI: 0.031, p = 0.239). Conclusion We developed a Lasso-Cox regression-based nomogram to stratify PFS risk in gastric carcinoma patients with double invasion. While the model outperformed AJCC staging in training, validation cohort results highlight the need for further refinement. This tool holds potential for guiding tailored therapeutic strategies, though broader validation is warranted to confirm clinical applicability. To identify high-risk gastric carcinoma patients with concurrent vascular and neural invasion ("double invasion") who are at heightened risk of progression-free survival (PFS) decline, enabling personalized clinical management. In this multi-center retrospective study, 559 patients with double invasion who underwent curative gastrectomy between May 2002 and December 2020 were analyzed. Prognostic factors for PFS were identified using Lasso-Cox regression. Model validation included internal bootstrapping, calibration plots, and comparison against the American Joint Committee on Cancer(AJCC) 8th edition TNM staging system via Harrell's C-index, decision curve analysis (DCA), and time-dependent receiver operating characteristic (ROC) curves. The nomogram integrated gender, positive lymph node count, surgical gastrectomy method, PTEN/FHIT expression levels, and maximum tumor diameter. It demonstrated superior predictive accuracy to AJCC staging, with a C-index of 0.651 (95% CI: 0.612-0.691) versus 0.543 (95% CI: 0.517-0.569). Calibration plots showed strong agreement between predicted and observed outcomes. The area under the curve(AUC) for 3- and 5-year PFS predictions were 0.719 (95% CI: 0.655-0.771) and 0.767 (95% CI: 0.670-0.841), respectively. DCA confirmed clinical utility across decision thresholds, and risk stratification effectively differentiated low- and high-risk groups. In the training cohort, the model significantly outperformed AJCC staging (NRI: 0.218, p < 0.01; IDI: 0.085, p < 0.01). However, this superiority was not statistically significant in the validation cohort (NRI: 0.141, p = 0.08; IDI: 0.031, p = 0.239). We developed a Lasso-Cox regression-based nomogram to stratify PFS risk in gastric carcinoma patients with double invasion. While the model outperformed AJCC staging in training, validation cohort results highlight the need for further refinement. This tool holds potential for guiding tailored therapeutic strategies, though broader validation is warranted to confirm clinical applicability. |
ArticleNumber | 381 |
Audience | Academic |
Author | Chang, Yu Ma, Jinfeng Qu, Wenqing Li, Yifan Wang, Liwei |
Author_xml | – sequence: 1 givenname: Liwei surname: Wang fullname: Wang, Liwei – sequence: 2 givenname: Yu surname: Chang fullname: Chang, Yu – sequence: 3 givenname: Jinfeng surname: Ma fullname: Ma, Jinfeng – sequence: 4 givenname: Wenqing surname: Qu fullname: Qu, Wenqing – sequence: 5 givenname: Yifan surname: Li fullname: Li, Yifan |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/40022037$$D View this record in MEDLINE/PubMed |
BookMark | eNptk92O1CAUxxuzxv3QF_DCNDExetEVaCnUG7PZ-DHJJiZ-XBNKoWVkYIR2sjNX-yD6Kj7MPol0ZnadGgMJJ_A7_3M4cE6TI-usTJKnEJxDSMvXASJKcQYQzmBOIcg2D5ITWBCYoQKQowP7ODkNYQ4AJBTQR8lxAQBCICcnye9ZI22v1VrbNu1022Veh--p4LbRDe9lSJXz6dI742w7MtFsvQxBO5spL2UaBr_SK25SbeOhXnC_Tlseeq9FlPFCW7fgkarnUvRp79Lbm5-NG2ojo8eKj0K3N7_epNzGyc261yKK8WUMxEWXDr02ejNGNjwElwl3nXp5l8Lj5KHiJsgn-_Us-fb-3dfLj9nVpw-zy4urTGAK-qxShDQKcoKBqAkpVYEUriiVUCgIqKpJXZNKQUxySlRJylIUqFbRbqgoCcjPktlOt3F8zvbXZI5rtt1wvmXcx8yNZERWeVnzhtOaFrVSFVZ1hQuEBAZQijJqvd1pLYd6IRsR6--5mYhOT6zuWOtWLD46gQSM2bzcK3j3Y5ChZwsdhDSGW-mGwHJIECEkRyP6_B907gYf67ylcAEgBvgv1fJ4A22Vi4HFKMouKKoQLko8ap3_h4qjkQst4t9UOu5PHF5NHCLTy-u-5UMIbPbl85R9ccB2kpu-C87E53c2TMFnh-W7r9vdn44A2gHCuxC8VPcIBGMNS7ZrHBYbh20bh23yP-EuD-Y |
Cites_doi | 10.3389/fmed.2024.1344982 10.3748/wjg.v9.i1.35 10.3748/wjg.v30.i6.542 10.1371/journal.pone.0266805 10.3322/caac.21660 10.5858/arpa.2015-0404-OA 10.1038/s41416-021-01408-8 10.18632/oncotarget.22369 10.1186/s12880-024-01200-z 10.1093/bjs/znab460 10.3389/fimmu.2024.1451725 10.1007/s10120-017-0716-7 10.1093/jjco/hyr179 10.1200/JCO.2014.58.3930 10.1186/s12957-021-02400-5 10.3389/fonc.2020.00326 10.1245/s10434-024-15939-w 10.1086/340026 10.7314/APJCP.2014.15.1.17 10.1007/s00018-014-1722-0 10.1002/jso.23940 10.2478/v10042-009-0010-6 10.1073/pnas.0605821103 10.1016/j.ctrv.2019.101889 10.1186/s12885-024-11929-z 10.1158/1055-9965.EPI-13-1057 10.1002/path.4287 10.2214/AJR.19.21875 10.1089/thy.2006.16.17 10.1002/sim.4154 10.1053/j.gastro.2018.01.068 10.1186/s13046-023-02730-0 10.3389/fphar.2024.1452201 10.3389/fonc.2022.882278 10.4149/neo_2020_200422N427 10.3389/fsurg.2022.916483 10.3389/fimmu.2017.00892 10.1111/cas.13032 10.1097/01.pai.0000213127.96590.2d 10.1007/s00268-013-2385-y 10.1007/s10555-019-09803-7 10.1097/PAS.0000000000001181 10.1016/S1470-2045(14)70473-5 10.1093/bioinformatics/btaa1046 10.3389/fphar.2023.1124262 10.1038/nrdp.2017.36 10.1186/s12957-023-03097-4 10.1186/s12974-024-03040-8 10.18632/oncotarget.18087 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4 10.1016/j.gendis.2022.12.015 10.1128/MCB.00004-10 10.1038/sj.onc.1209323 10.3389/fonc.2024.1382818 10.18632/oncotarget.10484 10.1186/s12957-024-03481-8 10.1073/pnas.1422640112 10.3390/jpm13050734 10.3390/cancers16030614 10.1007/s00109-011-0844-1 |
ContentType | Journal Article |
Copyright | 2025. The Author(s). COPYRIGHT 2025 BioMed Central Ltd. 2025. This work is licensed under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2025 2025 |
Copyright_xml | – notice: 2025. The Author(s). – notice: COPYRIGHT 2025 BioMed Central Ltd. – notice: 2025. This work is licensed under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2025 2025 |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM ISR 3V. 7TO 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
DOI | 10.1186/s12885-025-13810-z |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Science ProQuest Central (Corporate) Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni Edition) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) Medical Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | Publicly Available Content Database MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1471-2407 |
EndPage | 16 |
ExternalDocumentID | oai_doaj_org_article_7e936bada8b84bff95fb95422c501ec6 PMC11871700 A829254650 40022037 10_1186_s12885_025_13810_z |
Genre | Multicenter Study Journal Article |
GeographicLocations | China |
GeographicLocations_xml | – name: China |
GrantInformation_xml | – fundername: the Science and Education Cultivation Fund of the National Cancer and Regional Medical center of Shanxi Provincial Cancer hospital grantid: SD2023005 – fundername: Shanxi Provincial Key Discipline Special Fund grantid: No: 2025051 |
GroupedDBID | --- 0R~ 23N 2WC 53G 5VS 6J9 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL AAYXX ABDBF ABUWG ACGFO ACGFS ACIHN ACMJI ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR IHW INH INR ISR ITC KQ8 LGEZI LOTEE M1P M48 M~E NADUK NXXTH O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SBL SOJ SV3 TR2 TUS U2A UKHRP W2D WOQ WOW XSB CGR CUY CVF ECM EIF NPM PMFND 3V. 7TO 7XB 8FK AZQEC DWQXO H94 K9. PKEHL PQEST PQUKI PRINS 7X8 5PM PUEGO |
ID | FETCH-LOGICAL-c580t-9f77df1a750cb776f42f5988e1cf108fb7bb79f157387f6766c42bf87fd8c6703 |
IEDL.DBID | M48 |
ISSN | 1471-2407 |
IngestDate | Wed Aug 27 01:30:30 EDT 2025 Thu Aug 21 18:27:29 EDT 2025 Mon Jul 21 11:47:27 EDT 2025 Fri Jul 25 21:28:32 EDT 2025 Tue Jun 17 22:00:27 EDT 2025 Tue Jun 10 20:59:32 EDT 2025 Fri Jun 27 05:15:59 EDT 2025 Thu May 22 21:23:40 EDT 2025 Mon Jul 21 05:57:45 EDT 2025 Tue Aug 05 12:14:38 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Gastric cancer Progression-free survival Nomogram Risk stratification Vascular invasion and neural invasion |
Language | English |
License | 2025. The Author(s). Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c580t-9f77df1a750cb776f42f5988e1cf108fb7bb79f157387f6766c42bf87fd8c6703 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s12885-025-13810-z |
PMID | 40022037 |
PQID | 3175401505 |
PQPubID | 44074 |
PageCount | 16 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_7e936bada8b84bff95fb95422c501ec6 pubmedcentral_primary_oai_pubmedcentral_nih_gov_11871700 proquest_miscellaneous_3172777320 proquest_journals_3175401505 gale_infotracmisc_A829254650 gale_infotracacademiconefile_A829254650 gale_incontextgauss_ISR_A829254650 gale_healthsolutions_A829254650 pubmed_primary_40022037 crossref_primary_10_1186_s12885_025_13810_z |
PublicationCentury | 2000 |
PublicationDate | 2025-02-28 |
PublicationDateYYYYMMDD | 2025-02-28 |
PublicationDate_xml | – month: 02 year: 2025 text: 2025-02-28 day: 28 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: London |
PublicationTitle | BMC cancer |
PublicationTitleAlternate | BMC Cancer |
PublicationYear | 2025 |
Publisher | BioMed Central Ltd BioMed Central BMC |
Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
References | H Sung (13810_CR1) 2021; 71 JP Fan (13810_CR32) 2020; 67 P Li (13810_CR43) 2024; 31 H Zheng (13810_CR41) 2007; 15 F Alvarez-Nuñez (13810_CR24) 2006; 16 S Semba (13810_CR38) 2006; 25 J Czyzewska (13810_CR40) 2009; 47 J Chu (13810_CR47) 2022; 17 HH Van Acker (13810_CR52) 2017; 8 MJ Bourke (13810_CR3) 2018; 154 H Jia (13810_CR21) 2024; 16 13810_CR54 13810_CR55 J Wang (13810_CR61) 2024; 14 K Chen (13810_CR59) 2015; 112 J Galon (13810_CR28) 2014; 232 JR Karras (13810_CR36) 2016; 107 M Salati (13810_CR4) 2019; 79 R Cong (13810_CR9) 2024; 11 CE Waters (13810_CR35) 2014; 71 E Ünal (13810_CR22) 2020; 214 N Kemi (13810_CR56) 2019; 43 C Rodriguez-Mogeda (13810_CR51) 2024; 21 VE Strong (13810_CR7) 2015; 112 ANS Silva (13810_CR58) 2022; 109 A Ertay (13810_CR34) 2023; 10 A Biagioni (13810_CR6) 2019; 38 HT Ge (13810_CR11) 2024; 30 L Ciuffreda (13810_CR25) 2012; 90 KA Waite (13810_CR26) 2002; 70 FE Harrell Jr (13810_CR13) 1996; 15 A Cavazzoni (13810_CR31) 2017; 8 Z Zhu (13810_CR10) 2024; 24 J Zheng (13810_CR60) 2021; 125 H Uno (13810_CR12) 2011; 30 H Li (13810_CR42) 2024; 15 SH Park (13810_CR17) 2015; 33 L Yang (13810_CR27) 2003; 9 LS Peng (13810_CR53) 2016; 7 D Altree-Tacha (13810_CR48) 2017; 141 W Wang (13810_CR46) 2021; 36 Q Li (13810_CR57) 2023; 14 Y Li (13810_CR14) 2022; 9 P Karimi (13810_CR5) 2014; 23 UK Mukhopadhyay (13810_CR30) 2010; 30 Y Imai (13810_CR19) 2023; 13 H Katai (13810_CR8) 2018; 21 13810_CR33 JA Ajani (13810_CR2) 2017; 3 W Qu (13810_CR16) 2024; 22 K Matsuo (13810_CR23) 2021; 19 J Chen (13810_CR44) 2024; 24 A Takata (13810_CR49) 2014; 38 HC Zheng (13810_CR39) 2017; 8 WT Xu (13810_CR29) 2014; 15 F Bianchi (13810_CR37) 2006; 103 X Li (13810_CR20) 2023; 42 Y Li (13810_CR15) 2023; 21 B Luo (13810_CR45) 2022; 12 Y Satoh (13810_CR50) 2012; 42 SH Noh (13810_CR18) 2014; 15 |
References_xml | – volume: 11 start-page: 1344982 year: 2024 ident: 13810_CR9 publication-title: Front Med (Lausanne) doi: 10.3389/fmed.2024.1344982 – volume: 9 start-page: 35 issue: 1 year: 2003 ident: 13810_CR27 publication-title: World J Gastroenterol doi: 10.3748/wjg.v9.i1.35 – volume: 30 start-page: 542 issue: 6 year: 2024 ident: 13810_CR11 publication-title: World J Gastroenterol doi: 10.3748/wjg.v30.i6.542 – volume: 17 start-page: e0266805 issue: 4 year: 2022 ident: 13810_CR47 publication-title: PLoS ONE doi: 10.1371/journal.pone.0266805 – volume: 71 start-page: 209 issue: 3 year: 2021 ident: 13810_CR1 publication-title: CA Cancer J Clin doi: 10.3322/caac.21660 – volume: 141 start-page: 144 issue: 1 year: 2017 ident: 13810_CR48 publication-title: Arch Pathol Lab Med doi: 10.5858/arpa.2015-0404-OA – ident: 13810_CR54 – volume: 125 start-page: 277 issue: 2 year: 2021 ident: 13810_CR60 publication-title: Br J Cancer doi: 10.1038/s41416-021-01408-8 – volume: 8 start-page: 108261 issue: 64 year: 2017 ident: 13810_CR39 publication-title: Oncotarget doi: 10.18632/oncotarget.22369 – volume: 24 start-page: 20 issue: 1 year: 2024 ident: 13810_CR10 publication-title: BMC Med Imaging doi: 10.1186/s12880-024-01200-z – volume: 109 start-page: 291 issue: 3 year: 2022 ident: 13810_CR58 publication-title: Br J Surg doi: 10.1093/bjs/znab460 – ident: 13810_CR55 doi: 10.3389/fimmu.2024.1451725 – volume: 21 start-page: 144 issue: 1 year: 2018 ident: 13810_CR8 publication-title: Gastric Cancer doi: 10.1007/s10120-017-0716-7 – volume: 42 start-page: 148 issue: 2 year: 2012 ident: 13810_CR50 publication-title: Jpn J Clin Oncol doi: 10.1093/jjco/hyr179 – volume: 33 start-page: 3130 issue: 28 year: 2015 ident: 13810_CR17 publication-title: J Clin Oncol doi: 10.1200/JCO.2014.58.3930 – volume: 19 start-page: 291 issue: 1 year: 2021 ident: 13810_CR23 publication-title: World J Surg Oncol doi: 10.1186/s12957-021-02400-5 – ident: 13810_CR33 doi: 10.3389/fonc.2020.00326 – volume: 31 start-page: 8317 issue: 12 year: 2024 ident: 13810_CR43 publication-title: Ann Surg Oncol doi: 10.1245/s10434-024-15939-w – volume: 70 start-page: 829 year: 2002 ident: 13810_CR26 publication-title: Am J Hum Genet doi: 10.1086/340026 – volume: 15 start-page: 17 issue: 1 year: 2014 ident: 13810_CR29 publication-title: Asian Pac J Cancer Prev doi: 10.7314/APJCP.2014.15.1.17 – volume: 71 start-page: 4577 issue: 23 year: 2014 ident: 13810_CR35 publication-title: Cell Mol Life Sci doi: 10.1007/s00018-014-1722-0 – volume: 112 start-page: 31 issue: 1 year: 2015 ident: 13810_CR7 publication-title: J Surg Oncol doi: 10.1002/jso.23940 – volume: 47 start-page: 47 issue: 1 year: 2009 ident: 13810_CR40 publication-title: Folia Histochem Cytobiol doi: 10.2478/v10042-009-0010-6 – volume: 103 start-page: 18981 issue: 50 year: 2006 ident: 13810_CR37 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0605821103 – volume: 79 start-page: 101889 year: 2019 ident: 13810_CR4 publication-title: Cancer Treat Rev doi: 10.1016/j.ctrv.2019.101889 – volume: 24 start-page: 254 issue: 1 year: 2024 ident: 13810_CR44 publication-title: BMC Cancer doi: 10.1186/s12885-024-11929-z – volume: 23 start-page: 700 issue: 5 year: 2014 ident: 13810_CR5 publication-title: Cancer Epidemiol Biomarkers Prev doi: 10.1158/1055-9965.EPI-13-1057 – volume: 232 start-page: 199 issue: 2 year: 2014 ident: 13810_CR28 publication-title: J Pathol doi: 10.1002/path.4287 – volume: 214 start-page: W67 issue: 1 year: 2020 ident: 13810_CR22 publication-title: AJR Am J Roentgenol doi: 10.2214/AJR.19.21875 – volume: 16 start-page: 17 issue: 1 year: 2006 ident: 13810_CR24 publication-title: Thyroid doi: 10.1089/thy.2006.16.17 – volume: 30 start-page: 1105 issue: 10 year: 2011 ident: 13810_CR12 publication-title: Stat Med doi: 10.1002/sim.4154 – volume: 154 start-page: 1887 issue: 7 year: 2018 ident: 13810_CR3 publication-title: Gastroenterology doi: 10.1053/j.gastro.2018.01.068 – volume: 42 start-page: 206 issue: 1 year: 2023 ident: 13810_CR20 publication-title: J Exp Clin Cancer Res doi: 10.1186/s13046-023-02730-0 – volume: 15 start-page: 1452201 year: 2024 ident: 13810_CR42 publication-title: Front Pharmacol doi: 10.3389/fphar.2024.1452201 – volume: 12 start-page: 882278 year: 2022 ident: 13810_CR45 publication-title: Front Oncol doi: 10.3389/fonc.2022.882278 – volume: 67 start-page: 1359 issue: 6 year: 2020 ident: 13810_CR32 publication-title: Neoplasma doi: 10.4149/neo_2020_200422N427 – volume: 9 start-page: 916483 year: 2022 ident: 13810_CR14 publication-title: Front Surg doi: 10.3389/fsurg.2022.916483 – volume: 8 start-page: 892 year: 2017 ident: 13810_CR52 publication-title: Front Immunol doi: 10.3389/fimmu.2017.00892 – volume: 107 start-page: 1590 issue: 11 year: 2016 ident: 13810_CR36 publication-title: Cancer Sci doi: 10.1111/cas.13032 – volume: 15 start-page: 432 issue: 4 year: 2007 ident: 13810_CR41 publication-title: Appl Immunohistochem Mol Morphol doi: 10.1097/01.pai.0000213127.96590.2d – volume: 38 start-page: 1107 issue: 5 year: 2014 ident: 13810_CR49 publication-title: World J Surg doi: 10.1007/s00268-013-2385-y – volume: 38 start-page: 537 issue: 3 year: 2019 ident: 13810_CR6 publication-title: Cancer Metastasis Rev doi: 10.1007/s10555-019-09803-7 – volume: 43 start-page: 229 issue: 2 year: 2019 ident: 13810_CR56 publication-title: Am J Surg Pathol doi: 10.1097/PAS.0000000000001181 – volume: 15 start-page: 1389 issue: 12 year: 2014 ident: 13810_CR18 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(14)70473-5 – volume: 36 start-page: 5405 issue: 22–23 year: 2021 ident: 13810_CR46 publication-title: Bioinformatics doi: 10.1093/bioinformatics/btaa1046 – volume: 14 start-page: 1124262 year: 2023 ident: 13810_CR57 publication-title: Front Pharmacol doi: 10.3389/fphar.2023.1124262 – volume: 3 start-page: 17036 year: 2017 ident: 13810_CR2 publication-title: Nat Rev Dis Primers doi: 10.1038/nrdp.2017.36 – volume: 21 start-page: 207 issue: 1 year: 2023 ident: 13810_CR15 publication-title: World J Surg Oncol doi: 10.1186/s12957-023-03097-4 – volume: 21 start-page: 48 issue: 1 year: 2024 ident: 13810_CR51 publication-title: J Neuroinflammation doi: 10.1186/s12974-024-03040-8 – volume: 8 start-page: 53068 issue: 32 year: 2017 ident: 13810_CR31 publication-title: Oncotarget doi: 10.18632/oncotarget.18087 – volume: 15 start-page: 361 issue: 4 year: 1996 ident: 13810_CR13 publication-title: Stat Med doi: 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4 – volume: 10 start-page: 2511 issue: 6 year: 2023 ident: 13810_CR34 publication-title: Genes Dis doi: 10.1016/j.gendis.2022.12.015 – volume: 30 start-page: 4980 issue: 21 year: 2010 ident: 13810_CR30 publication-title: Mol Cell Biol doi: 10.1128/MCB.00004-10 – volume: 25 start-page: 2860 issue: 20 year: 2006 ident: 13810_CR38 publication-title: Oncogene doi: 10.1038/sj.onc.1209323 – volume: 14 start-page: 1382818 year: 2024 ident: 13810_CR61 publication-title: Front Oncol doi: 10.3389/fonc.2024.1382818 – volume: 7 start-page: 55222 issue: 34 year: 2016 ident: 13810_CR53 publication-title: Oncotarget doi: 10.18632/oncotarget.10484 – volume: 22 start-page: 196 issue: 1 year: 2024 ident: 13810_CR16 publication-title: World J Surg Oncol doi: 10.1186/s12957-024-03481-8 – volume: 112 start-page: 1107 issue: 4 year: 2015 ident: 13810_CR59 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.1422640112 – volume: 13 start-page: 734 issue: 5 year: 2023 ident: 13810_CR19 publication-title: J Pers Med doi: 10.3390/jpm13050734 – volume: 16 start-page: 614 issue: 3 year: 2024 ident: 13810_CR21 publication-title: Cancers (Basel) doi: 10.3390/cancers16030614 – volume: 90 start-page: 667 issue: 6 year: 2012 ident: 13810_CR25 publication-title: J Mol Med (Berl) doi: 10.1007/s00109-011-0844-1 |
SSID | ssj0017808 |
Score | 2.4415517 |
Snippet | To identify high-risk gastric carcinoma patients with concurrent vascular and neural invasion ("double invasion") who are at heightened risk of... Objective To identify high-risk gastric carcinoma patients with concurrent vascular and neural invasion ("double invasion") who are at heightened risk of... ObjectiveTo identify high-risk gastric carcinoma patients with concurrent vascular and neural invasion (“double invasion”) who are at heightened risk of... Abstract Objective To identify high-risk gastric carcinoma patients with concurrent vascular and neural invasion (“double invasion”) who are at heightened risk... |
SourceID | doaj pubmedcentral proquest gale pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database |
StartPage | 381 |
SubjectTerms | Accuracy Adult Aged Biomarkers Calibration Cancer invasiveness Cancer therapies Carcinoma Chemotherapy Complications and side effects Datasets Development and progression Female Gastrectomy Gastric cancer Gastrointestinal surgery Health aspects Hospitals Humans Lymph nodes Lymphatic system Male Medical records Middle Aged Neoplasm Invasiveness Neoplasm Staging Nomogram Nomograms Nomography (Mathematics) Patients Prognosis Progression-Free Survival Proportional Hazards Models PTEN protein Retrospective Studies Risk Assessment Risk Factors Risk groups Risk stratification ROC Curve Statistical analysis Stomach cancer Stomach Neoplasms - mortality Stomach Neoplasms - pathology Stomach Neoplasms - surgery Surgical outcomes Variables Vascular invasion and neural invasion |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbtQwELZQD4gL4p9AAYOQOKCo-fFfuBVEVZDKAajUm2U79rLSkkibXdTuqQ8Cr8LD9EmYcZLVRhy4IO0hWk_sxPN5PHZmPhPysuQGeSxtyp1TKSvrkFbgtoIx5KKqjfO5wX3Ik0_i-JR9PONnO0d9YUxYTw_cd9yB9FUprKmNsorZECoebMVZUTie5d5Fsm2Y88bF1PD9QKpMjSkyShx0YIUVZiJz5NwDy7OZTEORrf9vm7wzKU0DJndmoKNb5ObgOtLD_pFvk2u-uUOunwwfx--S333SbUxcokhDnGLcOHWYuILr-o6Cg0qh2UWLJIQzGmOzel6ONCy9p90aDAdAj84bKIw0FHRm8GQPB9UsoZn2uwEpi5s3dNXSq8ufdbu2Cw93_DBY0dXlrzfUNPAzi4u4T05H2nIKGF_MN9gyuuxt6tpzuvTjI9wjp0fvv747TofjGVLHVbZKqyBlHXIDPoezUorAisArpXzuQp6pYKW1sgo5l6WSQUghHCtsgOtaOQGW5j7Za9rGPyS0cEZU1oHtkAXjrFYeaQi5h0tfSMsS8nrUlh5eX8fVixK6160G3eqoW71JyFtU6FYSGbTjH4ArPeBK_wtXCXmGcNB9OurWDuhDVVR4hgDPEvIiSiCLRoNhOjOz7jr94cvnidCrQSi0AB1nhqwHeG8k3ppI7k8kYZi7afGISz2YmU6j88dwz4on5Pm2GO_E0LnGt-soU0gpywKqeNDDeNszDF24rJQJUROAT7puWtLMv0UScjymHrkdH_2Pzn5MbhQ4OCNVwD7ZWy3X_gk4eyv7NI7rP8UTWRo priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3NbtQwELagSIgL4p9AAYOQOKCo-fNPuKCCqApSOQCV9mbZjr1daUkg2UWwpz4IvAoP0ydhxkmWRkhIe4jWkzjJjD-PnZlvCHmaM408liZm1sq4yCsfl-C2AhgyXlbaulTjPuTRe354XLybsdmw4dYNYZUjJgagrhqLe-R7OM8VuDxnL798jbFqFH5dHUpoXCSXkLoMQ7rEbLvgSoVM5JgoI_leB1gsMR-ZIfMe4M9mMhkFzv5_kfnc1DQNmzw3Dx1cI1cHB5Lu9xq_Ti64-ga5fDR8Ir9JfveptyF9iSIZcYzR49Ri-gqu7jsKbiqFbpcNUhHOaYjQ6tk5Yt86R7s1wAcYIF3U0BjIKOhcY30PC5dpoZvmswYpg1s4dNXQs9OfVbM2SwdnfNN4obPTXy-oruGnlz_CbjkdycspWPpyscGe0XFvYtt8p60bb-EWOT548-n1YTwUaYgtk8kqLr0QlU81eB7WCMF9kXlWSulS69NEeiOMEaVPmcil8FxwbovMeDiupOWAN7fJTt3U7i6hmdW8NBYQRGQFKyrpkIyQOTh0mTBFRJ6P2lLD46uwhpFc9bpVoFsVdKs2EXmFCt1KIo92-KNp52oYlkq4MudGV1oaWRjvS-ZNyYossyxJneUReYTmoPqk1C0aqH2ZlVhJgCUReRIkkEujxmCduV53nXr78cNE6Nkg5BswHauH3Ad4bqTfmkjuTiRhsNtp82iXagCbTv0dGhF5vG3GMzGArnbNOshkQog8g0vc6c14-2YKdOSSXERETgx88uqmLfXiJFCRY7F6ZHi89__7uk-uZDjsAhXALtlZtWv3AJy5lXkYRuwfsCZPmQ priority: 102 providerName: ProQuest |
Title | Identifying high-risk candidates for prolonging progression-free survival in primary gastric carcinoma subject to “double invasion”: an analytical approach utilizing lasso-cox regression |
URI | https://www.ncbi.nlm.nih.gov/pubmed/40022037 https://www.proquest.com/docview/3175401505 https://www.proquest.com/docview/3172777320 https://pubmed.ncbi.nlm.nih.gov/PMC11871700 https://doaj.org/article/7e936bada8b84bff95fb95422c501ec6 |
Volume | 25 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dbtMwFLb2I027QfxTGMUgJC5QWJvGsYOE0Io2DaROqFCp4sayHbtUKolIW7T1ag8Cr8LD7Ek4x0lKI3aFFEVRfWw39vmz4_MdQp73mEIcSx0wY0QQ9VIXJOC2gjJkcZIqY7sK9yEHZ_HpKPowZuMtUqc7qgZwfu3SDvNJjYrZq_PvF29B4N94gRfx4Rx0rMA4Y4aIeqBXVttkFywTR0EdRH-_KnDREXXgzLX19slehFatg2nRN-yUh_P_V2lvWK3micoNE3Vyk9yofEt6VDLDLbJls9tkb1B9Pb9DfpdRuT6yiSJOcYAHy6nByBZc-M8peLAUup3liFI4of7wVgncEbjCWjpfgmYB3qTTDAo9TgWdKEz9YaCZArrJvymg0ri7Qxc5vbr8meZLPbNQ44fChq4uf72mKoNLzS78Rjqtcc0pCMFsusKe0afPA5Of08LWf-EuGZ0cf353GlT5GwLDRGcRJI7z1HUVOCVGcx67KHQsEcJ2jet2hNNca564LuM9wV3M49hEoXbwnAoTgyq6R3ayPLMPCA2NihNtQLnwMGJRKiziFDILjzbkOmqRl_Vsyer1pV_eiFiW0yxhmqWfZrlqkT5O6JoSIbb9D3kxkZXESm6TXqxVqoQWkXYuYU4nLApDwzpda-IWeYLsIMt41bWikEciTDDJAOu0yDNPgTAbGZ7jmajlfC7ffxo2iF5URC4H1jGqCouA90ZkrgblQYMS9IBpFtd8KWsxkugdRripxVrk6boYa-LZuszmS08Tcs57ITRxv2Tj9cjU0tAiosHgjaFrlmTTrx6lHPPYI_jjw_-v-ojshyidHkHggOwsiqV9DD7gQrfJNh_zNtntH599HLb9TkrbCzvch_0vfwBQy2US |
linkProvider | Scholars Portal |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtQwELZKKwEXxD8LhRoE4oCi7jpx7CAh1EKrlv4IlVbqzdiOvVRaEtjsAu2pDwKvwCPwMH0SZpxkIULiVmkP0XpiJ5nxN_6Z-UzI45hr5LE0EbdWRkmc-yiDYSuAIU-zXFs30LgOubObbhwkbw754Rz52ebCYFhli4kBqPPS4hr5Mvq5BKfn_OWnzxGeGoW7q-0RGrVZbLnjrzBlq15svgb9PmFsfW3_1UbUnCoQWS77kyjzQuR-oMFVWiNE6hPmeSalG1g_6EtvhDEi8wMuYil8KtLUJsx4uM6lTaGDQL0XyEISw1Rmniysru2-3ZvtWwjZl21qjkyXK0B_iRnQHLn-APFOOu4vnBLwry_4yxl2AzX_8nzrV8mVZshKV2obu0bmXHGdXNxpNuVvkF91sm9ImKJIfxxhvDq1mDCD6wkVhYExhWZHJZIfDmmICav5QCI_do5WUwAsMHl6VEBhoL-gQ40nilioZgzNlB81SBlcNKKTkp6dfs_LqRk5uOOLxorOTn88p7qAnx4dh_V52tKlU-hbo6MTbBmnCmVky2907NpHuEkOzkWBt8h8URbuDqHM6jQzFjBLsIQnuXRIf8gdXDomTNIjz1ptqeb1VZg1yVTVulWgWxV0q056ZBUVOpNE5u7wRzkeqgYIlHBZnBqda2lkYrzPuDcZTxizvD9wNu2RJTQHVafBzvBHrUiW4dkFvN8jj4IEsncUGB401NOqUpvv9jpCTxshX4LpWN1kW8B7I-FXR3KxIwnwYrvFrV2qBt4q9acz9sjDWTHeiSF7hSunQYYJIWIGVdyuzXj2ZRIcOvZj0SOyY-CdT9ctKY4-BPJz-PYCOSXv_v-5lsiljf2dbbW9ubt1j1xm2AUDEcEimZ-Mp-4-DCUn5kHTfyl5f96Q8RuD4I20 |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Identifying+high-risk+candidates+for+prolonging+progression-free+survival+in+primary+gastric+carcinoma+subject+to+%E2%80%9Cdouble+invasion%E2%80%9D%3A+an+analytical+approach+utilizing+lasso-cox+regression&rft.jtitle=BMC+cancer&rft.au=Wang%2C+Liwei&rft.au=Chang%2C+Yu&rft.au=Ma%2C+Jinfeng&rft.au=Qu%2C+Wenqing&rft.date=2025-02-28&rft.pub=BioMed+Central&rft.eissn=1471-2407&rft.volume=25&rft_id=info:doi/10.1186%2Fs12885-025-13810-z&rft_id=info%3Apmid%2F40022037&rft.externalDocID=PMC11871700 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2407&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2407&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2407&client=summon |